Circ-ZFR Promotes Progression of Bladder Cancer by Upregulating WNT5A
WNT5A
bladder cancer
circZFR
miR-1270
miR-545
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
08
2020
accepted:
16
12
2020
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Bladder cancer is one of the most common cancers all over the world. CircZFR is a circular RNA and has been implicated in tumor generation and invasion. However, the exact role of circZFR in the development of bladder cancer (BCa) remains unknown. This study aimed to investigate the function of circZFR in BCa, and further to probe into the association between circ-ZFR, miR-545/miR-1270 and WNT5A. The expression of circZFR in BCa was quantified by qRT-PCR and was positively correlated with the prognosis of BCa patients. Next, the stable knockdown of circZFR BCa cell lines was established and the resulting capacities of proliferation, migration and invasion were measured. The association of circZFR with miR-1270/miR-545 was predicted by circinteractome prediction, and was confirmed by luciferase assay as well as RNA pull down assay. Furthermore, miRNA inhibitors, WNT5A overexpression and Pearson correlation analysis were used to examine the relationship between circZFR, miR-1270/miR-545 and WNT5A. The expression of CircZFR was up-regulated both in BCa tissues and in BCa cell lines, and was positively correlated with patient survival rates. Blocking of circZFR's expression by RNA inhibitors suppressed the proliferation, migration and invasion of BCa cells both CircZFR promotes the proliferation, migration and invasion of BCa cells by upregulating WNT5A signaling pathway
Sections du résumé
BACKGROUND
BACKGROUND
Bladder cancer is one of the most common cancers all over the world. CircZFR is a circular RNA and has been implicated in tumor generation and invasion. However, the exact role of circZFR in the development of bladder cancer (BCa) remains unknown. This study aimed to investigate the function of circZFR in BCa, and further to probe into the association between circ-ZFR, miR-545/miR-1270 and WNT5A.
METHODS
METHODS
The expression of circZFR in BCa was quantified by qRT-PCR and was positively correlated with the prognosis of BCa patients. Next, the stable knockdown of circZFR BCa cell lines was established and the resulting capacities of proliferation, migration and invasion were measured. The association of circZFR with miR-1270/miR-545 was predicted by circinteractome prediction, and was confirmed by luciferase assay as well as RNA pull down assay. Furthermore, miRNA inhibitors, WNT5A overexpression and Pearson correlation analysis were used to examine the relationship between circZFR, miR-1270/miR-545 and WNT5A.
RESULTS
RESULTS
The expression of CircZFR was up-regulated both in BCa tissues and in BCa cell lines, and was positively correlated with patient survival rates. Blocking of circZFR's expression by RNA inhibitors suppressed the proliferation, migration and invasion of BCa cells both
CONCLUSIONS
CONCLUSIONS
CircZFR promotes the proliferation, migration and invasion of BCa cells by upregulating WNT5A signaling pathway
Identifiants
pubmed: 33928018
doi: 10.3389/fonc.2020.596623
pmc: PMC8076638
doi:
Types de publication
Journal Article
Langues
eng
Pagination
596623Informations de copyright
Copyright © 2021 Luo, Miao, Ming, Tao and Shen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biosci Rep. 2019 Dec 20;39(12):
pubmed: 31746333
Lancet. 2016 Dec 3;388(10061):2796-2810
pubmed: 27345655
Arch Biochem Biophys. 2019 Jan;661:196-202
pubmed: 30468709
Biomed Pharmacother. 2018 Dec;108:347-354
pubmed: 30227328
Cell. 2016 Apr 7;165(2):289-302
pubmed: 27040497
Biochem Biophys Res Commun. 2018 Sep 3;503(1):56-61
pubmed: 29842886
Oncotarget. 2015 Apr 30;6(12):10239-52
pubmed: 25823923
Trends Genet. 2016 May;32(5):309-316
pubmed: 27050930
Cancer Res Treat. 2018 Oct;50(4):1396-1417
pubmed: 29361817
Am J Cancer Res. 2017 May 01;7(5):1096-1106
pubmed: 28560060
Int J Oncol. 2019 Aug;55(2):359-370
pubmed: 31268162
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Onco Targets Ther. 2019 Sep 13;12:7537-7550
pubmed: 31571906
Exp Biol Med (Maywood). 2017 Jun;242(11):1136-1141
pubmed: 28485684
Sci Signal. 2013 Mar 05;6(265):ra14
pubmed: 23462101
Cell Physiol Biochem. 2018;48(2):815-826
pubmed: 30032142
Nat Rev Urol. 2019 Aug;16(8):465-483
pubmed: 31289379
Adv Exp Med Biol. 2018;1087:67-79
pubmed: 30259358
Cancers (Basel). 2016 Aug 26;8(9):
pubmed: 27571105
Oncol Lett. 2019 Sep;18(3):2931-2938
pubmed: 31452774
Oncogene. 2018 Feb 1;37(5):555-565
pubmed: 28991235
Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3410-3416
pubmed: 31407591
J Cell Physiol. 2019 Jun;234(6):9225-9232
pubmed: 30362562
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
Dig Liver Dis. 2019 Oct;51(10):1446-1455
pubmed: 31147216
Int Urol Nephrol. 2018 Oct;50(10):1811-1819
pubmed: 30117016
Oncol Lett. 2019 Feb;17(2):2063-2068
pubmed: 30675273
Biochem Biophys Res Commun. 2018 Oct 28;505(2):346-352
pubmed: 30249393
Cancer Med. 2018 Jun;7(6):2452-2462
pubmed: 29733519
Nat Rev Genet. 2019 Nov;20(11):675-691
pubmed: 31395983
Cell Death Dis. 2019 Aug 13;10(8):616
pubmed: 31409777
Mol Oncol. 2019 Jul;13(7):1559-1576
pubmed: 31131537